BREAST CANCER BASE

Breast cancer is a systemic disease of the local performance. By operation, with chemotherapy, radiotherapy, endocrine therapy, immune therapy, Chinese medicine and therapy treatment, the treatment of breast cancer is low toxicity efficient optimization program. Clinical according to their clinical stage, histological classification, type and syndromes of individual patients, a reasonable selection of treatment methods for comprehensive treatment.

Chinese medicine believes that the incidence of breast cancer is a deficiency in a healthy atmosphere, viscera function of the recession on the basis of exogenous and endogenous the dampness and pathological bleeding such products locked, causing it to stagnate, and bruising, coagulation, drugs Coalescence Tongxinluo derived from milk. Therefore, the incidence of the disease is due to the development of virtual disease, which is a lie, a mixture of fascination process. Because of differences in the nature of accumulation, pathology product aimed at invigorating different, and each have different syndromes performance. Clinical treatment should be reinstated with Quxie Is all of the general principles. Tell one of the good bad Sheng, lesion location and determine the course of different stages of the rule law. General mainly early to Quxie popular supplement, not stay stressed Fuzheng evil is not to hurt the Quxu attack fill-up.

Medical treatment for the removal of the preferred, in combination with radiotherapy, of knowledge, endocrine therapy and immune therapy, clinical stage of the disease according to the different options and specific treatment.

Generally speaking, the clinical period and the Phase II breast cancer feasible radical mastectomy; Phase II patients need surgery after adjuvant therapy (chemotherapy, radiotherapy or hormone therapy); Phase III cases, preoperative radiotherapy and chemotherapy preparations for the treatment of radical operation has been good results; IV patients, as well Department transfer, mastectomy with mostly useless, only for radiotherapy, chemotherapy or hormone treatment. In recent years, because of breast cancer hormone receptor (ER), make ER-positive patients who receive anti-estrogen treatment, the obvious effect.

(1) Surgical Treatment

Surgical treatment of breast cancer remain the main means of treatment. Multiple operation, there is no unity of their choice views. Nearly 10 years ago, I, II surgical treatment of breast cancer surgery has significantly narrowed the scope of that classic Halstyed radical mastectomy in the treatment, II breast cancer treatment has little application. Various studies confirm abroad breast-conserving therapy with radical mastectomy, two groups of disease-free survival and recurrence-free survival and overall survival was no statistical difference. Therefore breast-conserving therapy has become for Western countries, Phase II of breast cancer treatments.

(2) breast cancer surgery treatment

1, blood adjuvant chemotherapy of breast cancer metastasis is the main reason for treatment failure, systemic chemotherapy can control blood transfer, is undoubtedly enhance long-term effect of breast cancer reasonable measures. In addition, hematogenous metastasis of breast cancer at an early stage can often occurred infer clinical diagnosis of breast cancer in time to 50% -60% have occurred in the transfer of blood, hidden in small foci in the body, it should be breast cancer as a systemic disease such as strengthening systemic treatment with systemic chemotherapy.

2, auxiliary radiation therapy after adjuvant radiotherapy is to reduce the effects of local recurrence is a local treatment means.

3, adjuvant endocrine therapy adjuvant endocrine therapy has been used for the treatment of primary breast cancer tiny metastases. Ovariectomy on the treatment of women in pre-menopausal breast cancer is not yet sure. Recent studies tend to use the surgical treatment of tamoxifen (TAM), a dose of 10-20mg / time, two times a day, sustained medication for 1-2 years or 3-5 years, should be replaced ineffective second line anti-estrogen drugs. Treatment time can be retarded tumor recurrence and improve survival.

Adjuvant therapy overall strategy : good indicator of prognosis, and hormone receptor-positive tumors of patients given TAM treatment; And right there armpit lymph node metastasis and other indicators of poor prognosis of patients, regardless of their estrogen receptor positive or negative, should be given adjuvant chemotherapy. In contrast with chemotherapy, hormonal therapy is the main beneficiary of postmenopausal patients.